Twist Bioscience (TWST) Stock Statistics & Valuation Metrics

Twist Bioscience has a market cap or net worth of $7.95B. The enterprise value is $6.35B.

Market Cap

$7.95B

Enterprise Value

$6.35B

Twist Bioscience has 65,832,420 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

65,832,420

Owned by Insiders

2.03%

Owned by Institutions

64.31%

Twist Bioscience’s return on equity (ROE) is -0.16 and return on invested capital (ROIC) is -24.15%.

Return on Equity (ROE)

-0.16

Return on Assets (ROA)

-0.12

Return on Invested Capital (ROIC)

-24.15%

Return on Capital Employed (ROCE)

-0.25

Revenue Per Employee

384.65K

Profits Per Employee

-79.34K

Employee Count

979

Asset Turnover

0.59

Inventory Turnover

6.56

The current PE Ratio of Twist Bioscience is -60.96. Twist Bioscience’s PEG ratio is 0.93.

PE Ratio

-60.96

PS Ratio

20.63

PB Ratio

18.95

Price to FCF

-95.68

Price to Operating Cash Flow

-159.14

PEG Ratio

0.93

In the last 12 months, Twist Bioscience had revenue of 376.57M and earned -77.67M in profits. Earnings per share was -1.30.

Revenue

376.57M

Gross Profit

191.00M

Operating Income

-136.26M

Pretax Income

-76.95M

Net Income

-77.67M

EBITDA

-52.10M

Earnings Per Share (EPS)

-1.30

In the last 12 months, operating cash flow was -53.07M and capital expenditures -40.05M, giving a free cash flow of -93.12M billion.

Operating Cash Flow

-53.07M

Free Cash Flow

-93.12M

Free Cash Flow per Share

-1.49

Twist Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-1.05%

Earnings Yield

-1.62%

Beta

1.69

52-Week Price Change

294.35%

50-Day Moving Average

151.02

200-Day Moving Average

91.98

Relative Strength Index (RSI)

39.31

Average Volume (3m)

2.34M

Twist Bioscience upcoming earnings date is Nov 12, 2026, Before Open (Not Confirmed).

Last Earnings Date

Aug 03, 2026

Next Earnings Date

Nov 12, 2026

Ex-Dividend Date

―

Twist Bioscience as a current ratio of 3.64, with Debt / Equity ratio of 29.03%

Current Ratio

3.64

Quick Ratio

3.33

Debt to Market Cap

0.04

Net Debt to EBITDA

0.88

Interest Coverage Ratio

0.00

In the past 12 months, Twist Bioscience has paid 719.00K in taxes.

Income Tax

719.00K

Effective Tax Rate

-0.01

Twist Bioscience EV to EBITDA ratio is -82.44, with an EV/FCF ratio of -95.42.

EV to Sales

20.58

EV to EBITDA

-82.44

EV to Free Cash Flow

-95.42

EV to Operating Cash Flow

-167.43

Twist Bioscience has $166.84M in cash and marketable securities with $93.59M in debt, giving a net cash position of $73.25M billion.

Cash & Marketable Securities

$166.84M

Total Debt

$93.59M

Net Cash

$73.25M

Net Cash Per Share

$1.11

Tangible Book Value Per Share

$5.62

Gross margin is 51.97%, with operating margin of -31.91%, and net profit margin of -31.66%.

Gross Margin

51.97%

Operating Margin

-31.91%

Pretax Margin

-31.46%

Net Profit Margin

-31.66%

EBITDA Margin

-24.96%

EBIT Margin

-30.84%

The average price target for Twist Bioscience is $168.88, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

$168.88

Price Target Upside

39.81% Upside

Analyst Consensus

Moderate Buy

Analyst Count

8

Revenue Growth Forecast

19.19%

EPS Growth Forecast

-53.86%

Smart Score

4

AI Score

59